Oyticker
LIVE
  1. Live market news
  2. Stocks
  3. BIIB

Biogen Inc

BIIBStockUSA

See in Charts
About

Biogen Inc

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis (collectively 45% of 2024 revenues); nusinersen (Spinraza) for the treatment of spinal muscular atrophy (16.2% of 2024 revenues); omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia (4.0% of 2024 revenues); tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars (8.2% of 2024 revenues) and has collaborations with Genentech for several drugs (18.1% of 2024 revenues).

The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000.

SEC filings

What BIIB filed

All its filings

From SEC EDGAR, the public record of what US-listed companies file. Each document opens on sec.gov.

Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.